A Physician Makes the Case for Peptide Therapy — and Admits the Evidence Gaps
A functional medicine doctor explains why they prescribe peptides like BPC-157 despite limited human trials, and the professional risk of saying so publicly.
A functional medicine physician published an unusually candid piece on KevinMD this week, laying out both their clinical case for using peptide therapy and the uncomfortable truth that the human trial data is thin. The piece focuses on compounds like BPC-157 and reflects a broader tension in the field: practitioners seeing what they describe as meaningful results in patients, while the formal research infrastructure has not yet caught up.
Details
The KevinMD article is written from the perspective of a clinician who uses peptides in practice and is willing to say so out loud, which the author frames as a professional risk in itself. That framing alone is telling. Peptide therapy, particularly around compounds like BPC-157, occupies a gray zone where clinical use has outpaced controlled human studies.
BPC-157, for those unfamiliar, is a synthetic peptide derived from a protein found in gastric juice. It has been studied in animal models for tissue repair, gut health, and anti-inflammatory effects. The animal data is fairly extensive. The human data is not. There are no large-scale randomized controlled trials in humans published to date, which is the standard most physicians and regulators require before endorsing a treatment.
The author does not dismiss this gap. Instead, they explain why they have chosen to work within it anyway, citing patient cases, the mechanistic plausibility of the research, and their assessment of the risk-to-benefit profile based on what is currently known. The article also touches on why more physicians do not speak openly about using these compounds, pointing to reputational and regulatory exposure.
That professional reluctance is a real factor in how information about peptide therapy spreads. Much of the visible advocacy comes from wellness influencers or compounding pharmacy marketing rather than clinicians, which does not help the field develop a more grounded evidence base.
Why It Matters
This kind of clinician-authored piece matters because it reflects something that is genuinely happening in medicine right now. Patients are asking about peptides. Some physicians are prescribing them. And the conversation is largely happening outside of peer-reviewed journals and formal clinical guidelines.
The article does not resolve the evidence question, but it makes the clinical reasoning visible in a way that is useful. Readers can see how a practitioner weighs incomplete data against patient need, which is a more honest picture than either uncritical promotion or flat dismissal.
For patients who are already curious about or using compounds like BPC-157, understanding that even supportive physicians acknowledge the trial gaps is important context. It does not mean the compounds are ineffective. It means the confidence level a clinician can reasonably hold is different from what the evidence might look like in five or ten years if proper trials get funded and completed.
The piece also highlights a structural problem. Research on peptides is expensive. Many of these compounds are not patentable, which reduces the commercial incentive to run the kind of Phase 2 and Phase 3 trials that would produce the data clinicians and regulators want to see. That funding gap is not unique to peptides, but it is particularly acute here.
What’s Next
Whether the human trial picture improves depends largely on academic research centers and government funding bodies picking up work that the private sector has little incentive to sponsor. Some researchers are pursuing BPC-157 and related peptides through investigator-initiated trials, but progress is slow and funding is competitive.
In the meantime, clinicians who use these compounds are likely to keep navigating the same tradeoffs the KevinMD author describes: incomplete evidence, interested patients, and a professional environment that does not always reward honesty about what is known versus what is assumed.
More physician voices entering this conversation publicly, as this article represents, could eventually help build a more serious clinical literature. But that process takes time.
Related Reading
Original Source
kevinmd.com →